AFTON DICKERSON: Open Payments
NPI 1497387393 · SHENANDOAH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,421 in 139 payments from 42 companies in 2025. Trend: 2023 $6,950 · 2024 $7,617 · 2025 $4,421
Food & beverage: $3,238Long term medical supply or device loan: $848Education: $335
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 26 | $1,273 |
| Merck Sharp & Dohme LLC | 11 | $369 |
| Gilead Sciences, Inc. | 6 | $311 |
| Janssen Biotech, Inc. | 14 | $296 |
| AstraZeneca Pharmaceuticals LP | 10 | $237 |
| ABBVIE INC. | 6 | $136 |
| Celgene Corporation | 5 | $118 |
| SpringWorks Therapeutics, Inc. | 3 | $101 |
| Eisai Inc. | 4 | $100 |
| Incyte Corporation | 1 | $99 |
Products named: KISQALI, Trodelvy, KEYTRUDA, Fabhalta, WELIREG, TAGRISSO, SCEMBLIX, Venclexta.
Industry payments across TX — which companies pay providers there.
